Longevity science advances with first aging-reversal drug in human trials

Longevity science is transitioning from theoretical research to clinical application, with a growing focus on extending ‘healthspan’—the period of life spent in good health—rather than just lifespan. In May 2026, Harvard University released a report detailing how biological hallmarks of aging, such as cellular senescence and mitochondrial dysfunction, are viewed as addressable root causes rather than inevitable declines.

A significant milestone occurred in June 2026 when the first drug designed to reverse aspects of aging entered human clinical trials, moving epigenetic reprogramming from animal models to human subjects.

While scientific interest grows, experts caution against unproven marketing claims. Ángel Durántez, director of the Neleva clinic in Spain, warns that while medical interventions may modulate the speed of aging, no current strategy can fully reverse it. He emphasizes that lifestyle factors—including physical activity, sleep hygiene, nutrition, and stress management—remain more effective than many emerging supplements or stem cell treatments that currently lack sufficient scientific evidence.